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Abstract
Objective: To investigate the association between visit-to-visit HbA1c variability and 
cardiovascular events and microvascular complications in patients with newly 
diagnosed type 2 diabetes.
Research Design and Methods: This retrospective cohort study analyzed patients 
from Tayside and Fife in the Scottish Care Information-Diabetes Collaboration (SCI-
DC), who were observable from the diagnosis of diabetes and had at least five HbA1c 
measurements before the outcomes being evaluated. We used the previously reported 
HbA1c variability score (HVS) calculated as the percentage of the number of changes 
in HbA1c over 0.5% (5.5 mmol/mol) among all HbA1c measurement within an 
individual. The association between HVS and ten outcomes was assessed using Cox 
proportional-hazards models.
Results: We included 13,111 to 19,883 patients in the analyses of each outcome. The 
patients with HVS over 60% were associated with elevated risks of all outcomes 
compared with the lowest quintile (for example, hazard ratios and 95% confidence 
intervals [HVS >80 to ≤100 vs. HVS ≥0 to ≤20]: 2.38 [1.61~3.53] for major adverse 
cardiovascular events [MACE]; 2.4 [1.72~3.33] for all-cause mortality; 2.4 [1.13~5.11] 
for atherosclerotic cardiovascular [ASCV] death; 2.63 [1.81~3.84] for coronary artery 
disease; 2.04 [1.12~3.73] for ischemic stroke; 3.23 [1.76~5.93] for heart failure; 7.4 
[3.84~14.27] for diabetic retinopathy; 3.07 [2.23~4.22] for diabetic peripheral 
neuropathy; 5.24 [2.61~10.49] for diabetic foot ulcer; 3.49 [2.47~4.95] for the new-
onset chronic kidney disease). Four sensitivity analyses, including adjustment for time-
weighted average HbA1c confirmed the robustness of the results. 
Conclusions: Our study shows that higher HbA1c variability is associated with 
increased risks of all-cause mortality, cardiovascular events and microvascular 
complication of diabetes independently of high HbA1c. 
Keywords: HbA1c variability, cardiovascular event, all-cause mortality, heart failure, 
diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot ulcer, chronic kidney 
disease
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Introduction
Although there is considerable evidence that intensive blood glucose normalization 
reduces the risk of both cardiovascular events and microvascular complications of 
diabetes (1-3), the effects were heterogeneous between trials. For example, the 
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was terminated 
prematurely due to significantly elevated mortality and cardiovascular events (4), 
suggesting that the near-normalization of blood glucose should not be the only target 
of diabetes treatment. Glycemic variability is one factor that may explain these 
differences in cardiovascular outcomes.
Glycemic variability can be measured as either the glucose fluctuation within a day or 
the long-term visit-to-visit variability. The latter has been recently investigated in 
several studies, although the metrics and definition of the variability measure were 
inconsistent (5). Most studies evaluating HbA1c variability using the standard deviation 
(SD) or the coefficient of variation (CV) of HbA1c, suggested that these measures were 
associated with all-cause mortality and the development of the adverse outcomes of 
diabetes, after adjusting for the average HbA1c (6-11). However, neither SD or CV of 
HbA1c can be easily interpreted in clinical practice. Recently, Forbes and colleagues 
(12) developed a new scale, namely the HbA1c variability score (HVS) in the current 
study, to define the HbA1c variability. The HVS indicates how frequently the HbA1c 
rises or decreases by more than 0.5% (5.5mmol/mol), which is in line with the SD and 
CV of HbA1c but clinically more translatable (as it can be interpreted as the percentage 
of total HbA1c measures that vary by more than 0.5% or 5.5mmol/mol) (6,12). 
However, the HVS has not been widely used among the studies of HbA1c variability, 
with previous studies using this scale only focusing on the elderly and non-diabetic 
population and evaluating mainly mortality as an outcome (6,12). It is unclear whether 
HVS is associated with microvascular complications of diabetes and whether the 
increased cardiovascular risk described could be extended to real-world patients with 
type 2 diabetes. In this study we aimed to investigate the association between visit-to-
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visit HbA1c variability and both cardiovascular diseases and microvascular 
complications in a large population database of patients with newly diagnosed type 2 
diabetes.
Research Design and Methods
Data source and study population
The population was selected from patients from Tayside and Fife in the Scottish Care 
Information-Diabetes Collaboration (SCI-DC), the electronic health record system used 
in Scotland for patients with diabetes. The patients were included if they: 1) were 
diagnosed with type 2 diabetes; 2) had their first HbA1c measurement within one year 
from diagnosis of diabetes; 3) were over 40 years old when first diagnosed with diabetes; 
4) did not experience any study outcome before or within three years since diagnosis of 
diabetes; 5) had at least five records of HbA1c measurement between diagnosis of 
diabetes and the first episode of the study outcome. Patients were excluded where data 
were incomplete (details see the Supplementary Techniques). Data provision and 
linkage were carried by the University of Dundee Health Informatics Centre (HIC, 
https://www.dundee.ac.uk/hic), with analyses of anonymized data performed in an 
ISO27001 and Scottish Government accredited secure safe haven. HIC Standard 
Operating Procedures have been reviewed and approved by the NHS East of Scotland 
Research Ethics Service and consent for this study was obtained from the NHS Fife 
Caldicott Guardian. 
Baseline parameters and follow-up
The body mass index (BMI), estimated glomerular filtration rate (eGFR), smoking 
status at baseline were captured from the medical record within one year from the 
diagnosis of diabetes (details see the Supplementary Techniques). The follow-up was 
defined by the first event of outcome or the last measurement of HbA1c before 24 April 
2017 in the event-free case. Charlson Co-morbidity Index (CCI) was calculated using 
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the ICD (International Classification of Diseases)-9 and ICD-10 code within the year 
after the diagnosis of diabetes (13), while we specifically removed the items of diabetes 
and cardiovascular events, which were overlapping with our population or outcomes. 
Assessment of visit-to-visit HbA1c variability
To avoid the interaction between the HbA1c variability parameter with the frequency 
of HbA1c measurement and to better fit clinical practice, the HbA1c variability was 
evaluated using HVS, which was adopted from a recent publication (12). Briefly, HVS 
is the number of measures within an individual where the HbA1c has changed by > 0.5% 
(5.5mmol/mol) from the value prior, as a percentage of the total number of HbA1c 
measures between the diagnosis of diabetes and the outcome of interest for that 
individual (Fig. S1). To avoid the impact of multiple HbA1c measures in a short space 
of time, we allocated one HbA1c measure for every three-month period, using the 
median of all the HbA1c measures within that time. The resulting variability measure 
is termed the binned HVS (b-HVS). We also calculated the time-weighted average 
HbA1c, which was calculated using the area under the curve (AUC) of HbA1c from the 
diagnosis of diabetes to the first event divided by the duration. 
Outcomes
We examined ten outcomes of interest including: major adverse cardiovascular events 
(MACE); all-cause mortality; atherosclerotic cardiovascular death (ASCV death); 
hospitalization or death from coronary artery disease, ischemic stroke or heart failure; 
observable background diabetic retinopathy (DR), diabetic peripheral neuropathy 
(DPN); diabetic foot ulcer (DFU); and the new onset of chronic kidney diseases (CKD). 
If the event of interest occurred within the first three years from the diagnosis of 
diabetes, the patient was excluded from the analysis of that outcome, to avoid the 
outcome occurring close to diagnosis before the HVS could be defined, when the 
outcome would be unlikely to be related to the HVS. For full definitions of the 
endpoints (see the Supplementary Techniques).
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Statistical Analyses
The categorical variables were described using frequency and percentage. The 
continuous variables were described using means and SDs if normally distributed or 
median interquartile range (IQR) if not. Cox proportional-hazards model was used to 
assess the association between the HbA1c variability and each of the outcomes. The 
association of the adverse outcome with the HVS categories (≥0 to ≤20, >20 to ≤40, >40 
to ≤60, >60 to ≤80, >80, with the ≥0 to ≤20 as reference) were adjusted for sex, index 
age, calendar year, Scottish Index of Multiple Deprivation (SIMD) quintiles, ever 
smoking, hypertension at baseline, BMI at baseline, high-density lipoprotein (HDL) 
cholesterol at baseline, eGFR at baseline, antiplatelet therapy at baseline and CCI (≥1 
vs 0). We used Survival::cox.zph Pack in R to test the proportional hazards assumption 
for Cox regression models (14) for all our models. We considered the proportional 
hazards assumptions to be violated if the global P-value lower than 0.01. Because of 
the violation of proportional hazards assumptions the stage of CKD (stage 1 or 2) at 
baseline rather than the eGFR at baseline was stratified in the analysis of the new onset 
of the CKD. Five subgroup analyses were introduced based on the age (<65 years vs 
≥65 years), sex, BMI at baseline (>30kg/m2 vs ≤30kg/m2), time-weighted mean HbA1c 
(>7% vs ≤7% or >53mmol/mol vs ≤53mmol/mol), and treatment at baseline 
(medication/insulin-treated vs. lifestyle intervention only). Five sensitivity analyses 
were performed for each outcome by: 1) adjusting for time-weighted average HbA1c; 
2) using the b-HVS instead of HVS; 3) using the HVS based on the HbA1c 
measurement solely focusing on the first three years after diagnosis of diabetes, prior 
to the occurrence of any event; 4) using the individual-level SDs of the HbA1c instead 
of the HVS; 5) using individual-level CVs of HbA1c instead of the HVS. Analyses 
were undertaken in the SAS® 9.4 (SAS Institute Inc., Cary, NC, USA). and the RStudio 
for Windows (R version 3.2.5). 
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Results
Baseline characteristics
As shown in Fig. 1, among the 79,569 patients with type 2 diabetes identified in the 
population, we included 21,352 patients for further analysis., The average age was 63.3 
± 11.1 years when recruited and 54.6% of them were male. The median follow-up 
duration was 6.8 (IQR: 4.6~11.2) years. The mean HbA1c at baseline was 7.7% ± 2.0% 
(60.7 ± 21.4 mmol/mol), and the median number of HbA1c measurements throughout 
the study period was 12 (IQR: 8~19) times during the follow-up duration. Tab. S1 
shows the baseline patient characteristics for those included for each analysis of 
outcomes and Tab. 1 shows how the baseline characteristics differ across the HVS 
categories. 62% of the patients have an HVS below or equal to 40%; 12.5% have an 
HVS greater than 60%. As expected, an increasing HVS is associated with younger age 
of diagnosis, higher BMI, and more intensive diabetes treatment including greater 
insulin use.
HbA1c variability and outcomes
As shown in Fig. 2, between 13,111 to 19,883 patients were involved in the analyses 
of each outcome. Comparing with the reference (lowest HVS category, ≥0 to ≤20), 
patients with HVS over 60 were associated with increased risks of all outcomes in a 
fully adjusted Cox model. For example, those with HVS >80 to ≤100 had an increased 
risk of (HR [95%CI]): MACE: 2.38 [1.61~3.53]; all-cause mortality: 2.4 [1.72~3.33]; 
ASCV death: 2.4 [1.13~5.11]; coronary artery disease: 2.63 [1.81~3.84]; ischemic 
stroke: 2.04 [1.12~3.73]; heart failure: 3.23 [1.76~5.93]; DR: 7.4 [3.84~14.27]; DPN: 
3.07 [2.23~4.22]; DFU: 5.24 [2.61~10.49]; CKD: 3.49 [2.47~4.95]). 
Subgroup analyses and sensitivity analyses
Given the association between HVS and HbA1c we first undertook a sensitivity analysis, 
including time-weighted average HbA1c from diagnosis to event in the models (Fig. 
3). The results were similar for most outcomes other than retinopathy where the 
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association of HVS was diminished when adjusting for the time-weighted average 
HbA1c. 
When comparing the subgroups with time-weighted average HBA1c more than or less 
than 7% (53mmol/mol) there was a stronger association between the HVS and coronary 
artery disease, ischemic stroke and progression to CKD in patients with time-weighted 
average HbA1c<7% or 53mmol/mol (Fig. S5). Other subgroup analyses were 
undertaken based on age (Fig. S2), sex (Fig. S3), obesity at baseline (Fig. S4) and 
treatment at baseline (Fig. S6) did not show significant differences in the trend of the 
association (except the cases with very small sample size). Using b-HVS instead of 
HVS also showed consistent results in all outcomes (Fig. S7). However, the sensitivity 
analysis using the first-three year HVS suggested a weaker association compared with 
the main analysis (Fig. S8). The sensitivity analysis using the individual-level SD (Fig. 
S9) and CV (Fig. S10) of HbA1c showed a similar pattern of risk for most outcomes 
but not ischemic stroke for SD and CV and diabetic retinopathy for CV where weaker 
associations were observed.
Discussion
To our knowledge, this is the first population-based study to investigate the association 
between the visit-to-visit HbA1c variability and comprehensive endpoints including 
cardiovascular events and the microvascular complications of diabetes in patients with 
newly diagnosed type 2 diabetes independent of the time-weighted average HbA1c. 
Our study showed clear elevated risks of adverse events in the ~12.5% of patients with 
a HVS higher than 60 (meaning those with 60% of their HbA1c measurements 
increased or decreased by > 0.5% (5.5mmol/mol) compared with the last measurement) 
after diagnosis of diabetes adjusted for their time-weighted average HbA1c. The results 
were consistent with previous studies based on trial (15,16) and observational datasets 
(6-12,17). Our results indicate that frequent fluctuations of HbA1c of patients with 
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diabetes may be an independent risk factor of poor prognosis and more stable HbA1c 
control may benefit the patients in clinical practice, although it should be emphasized 
that our results are observational and causal inference cannot be made. Of note, a recent 
analysis based on the VADT trial (16) suggested that higher HbA1c variability was 
associated with the increased risk of cardiovascular events in the group of intensive 
glycemic control but not the standard control. It suggested that the increased HbA1c 
variability may neutralize the cardiovascular benefits of the sustained 1.5% (16.4 
mmol/mol) HbA1c reduction during the study period (18). We undertook a subgroup 
analysis looking at HVS in those with good and poor average HbA1c. It was interesting 
to note that the HVS association with atherosclerotic cardiovascular events was greater 
in those with good HbA1c, in keeping with the VADT finding. However, we need to 
interpret these results with caution as we can not account for treatment intensity during 
the study period.
We have previously reported that patients with high variability in HbA1c have high 
cardiovascular risk at baseline (19), and thus the association of HbA1c variability with 
risk may not be a feature of the HbA1c variability per se, but a marker of this baseline 
difference in patient characteristics. In this current study we have adjusted 
comprehensively for baseline differences in cardiovascular risk although we 
acknowledge there could be residual confounding. It is interesting to note that in the 
sensitivity analysis where we restrict our analysis to defining HbA1c variability only 
on the first three years of HbA1c measures, the association with micro- and 
macrovascular outcomes are diminished. This suggests that the HbA1c variability may 
continuously contribute to the clinical adverse endpoints beyond the first three years, 
and therefore that the risk can be less attributable to baseline differences in patient 
characteristics and more attributable to the HbA1c variability per se. As a recent study 
suggested that HbA1c variability is associated with the quality of patient care (20), it 
also suggests that it is never too late to reduce the HbA1c variability in clinical practice. 
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Although infeasible in the current analysis, it would also be interesting to evaluate 
HbA1c variability on different anti-diabetic treatments to see if reduced variability can 
explain some of the improved outcomes with some of these agents. 
Although we cannot attribute poor prognosis to the HbA1c variability per se, some 
underlying mechanisms may explain the association observed in our study. Although 
oxidative stress is suggested to be the explanation between short-term glycemic 
variability and adverse outcomes (5), it is not clear whether this is increased in patients 
with high visit-to-visit HbA1c variability. An alternative may relate to accumulated 
epigenetic modification induced by both high and low glycemia (21). Another 
explanation may simply relate to increased hypoglycemia in these individuals, since 
some studies suggest high HbA1c variability is linked to increased risk of severe 
hypoglycemic episodes (22) and patients admitted to hospital due to hypoglycemia have 
higher HbA1c variability (23). It will be valuable if a further study could address the 
frequency of overall and severe hypoglycemia among patients with different HbA1c 
variability.
The strengths of our study are clear. Firstly, all the included patients were tracked with 
their HbA1c measurement from the diagnosis of diabetes, so there is no period of the 
patients' diabetes journey that is not captured. Secondly, we comprehensively studied 
ten clinically important outcomes, including all-cause mortality, cardiovascular events 
and major microvascular complications of diabetes and showed consistent results 
across these micro- and macrovascular endpoints. Thirdly, our results were confirmed 
by a series of subgroup analyses and sensitivity analyses including adjusting for the 
time-weighted average HbA1c from the diagnosis of diabetes. Fourthly, our study was 
based on the real-world data of diabetes care in Scotland making these results directly 
translatable to clinical practice. Finally, we have used the HVS rather than SD or CV 
which we feel is much more clinically tractable. Although SD and CV reflect the 
dispersion trend of the HbA1c measures in an individual, they are no more than 
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clinically meaningless statistical parameters. When considering the HVS, the clinicians 
can review the HbA1c profile for an individual – those where more than 60% of 
measures vary by more than 0.5% are at high risk.
The study does have limitations. Firstly, as a retrospective cohort study, uncorrected 
confounding could be possible and individuals with higher HbA1c variability may also 
at higher cardiovascular risks of other causes (18), and we cannot conclude an 
association of variability per se with the outcomes. Nevertheless, we used Cox 
proportional-hazards models to minimize the possible known confounding factors 
including CCI, smoking status and social deprivation and used a series of subgroup 
analyses and sensitivity analyses to confirm our findings to be robust. Secondly, we did 
not adjust for or evaluate the contribution of hypoglycemia, which has been reported to 
be associated with HbA1c variability (15) in the association between the HbA1c 
variability and outcomes because of the limitation of the data. Thirdly, the median 
follow-up duration of the study was 6.8 years and this will limit the total incident 
outcomes. The need to only include patients with newly diagnosed diabetes and other 
inclusion criteria do limit the total follow up time in this study population. This 
relatively short median duration does reduce the number of long-term outcome events 
especially for retinopathy and diabetic foot ulcer. Studies with longer follow-up 
duration in larger populations would be of value.
Conclusion
In conclusion, our study shows that higher HbA1c variability from the diagnosis of 
diabetes is independently associated with increased risks of all-cause mortality, major 
cardiovascular and microvascular complications of diabetes. 
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Table and table legend
Table 1.  Baseline characteristics of the overall study population
HVS Scores ≥0 to ≤20 >20 to ≤40 >40 to ≤60 >60 to ≤80 >80
n 7,084 6,096 5,502 2,409 261
Age of diabetes diagnosis, yrs 67.1 ± 10.3 63.5 ± 10.5 60.5 ± 10.9 58.9 ± 11.2 57.5 ± 11.2
Sex (male), n (%) 3,569 (50.4) 3,305 (54.2) 3,179 (57.8) 1,446 (60.0) 165 (63.2)
SIMD quintile, n (%)
  Q1 1,251 (17.7) 1,165 (19.1) 1,171 (21.3) 503 (20.9) 62 (23.8)
  Q2 1,263 (17.8) 1,134 (18.6) 1,121 (20.4) 471 (19.6) 51 (19.5)
  Q3 1,328 (18.7) 1,175 (19.3) 1,016 (18.5) 493 (20.5) 52 (19.9)
  Q4 1,936 (27.3) 1,629 (26.7) 1,409 (25.6) 634 (26.3) 60 (23.0)
  Q5 1,306 (18.4) 993 (16.3) 785 (14.3) 308 (12.8) 36 (13.8)
Year of diabetes diagnosis* 2010 [2005, 
2012]
2008 [2002, 
2011]
2008 [2002, 
2011]
2009 [2003, 
2011]
2010 [2006, 
2013]
BMI, kg/m2 31.3 ± 6.0 31.9 ± 6.2 32.8 ± 6.5 33.3 ± 7.1 33.2 ± 7.3
Ever smoking, n (%) 4,881 (68.9) 4,336 (71.1) 3,977 (72.3) 1,748 (72.6) 178 (68.2)
Ever regular alcohol, n (%) 4,008 (61.2) 3,345 (59.1) 2,875 (57.3) 1,185 (54.5) 131 (56.5)
Systolic blood pressure, mmHg 140.1 ± 19.0 141.2 ± 19.5 140.3 ± 19.8 139.6 ± 19.6 138.2 ± 19.4
Diastolic blood pressure, mmHg 78.9 ± 10.8 81.0 ± 10.9 82.2 ± 11.2 82.2 ± 11.4 82.2 ± 12.0
Carlson Comorbidity Index ≥1, n (%) 1,332 (18.8) 1,073 (17.6) 867 (15.8) 449 (18.6) 58 (22.2)
Hypertension, n (%) 5,505 (77.7) 4,376 (71.8) 3,786 (68.8) 1,574 (65.3) 155 (59.4)
Treatment of diabetes within the first year from the 
diagnosis of diabetes, n (%)
  Lifestyle intervention only 5,260 (74.3) 3,137 (51.5) 2,190 (39.8) 740 (30.7) 61 (23.4)
  Anti-diabetic agents without insulin 1,770 (25.0) 2,821 (46.3) 3,153 (57.3) 1,569 (65.1) 188 (72.0)
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  Treated with insulin 54 (0.8) 138 (2.3) 159 (2.9) 100 (4.2) 12 (4.6)
Receiving anti-platelet therapy, n (%) 2,465 (34.8) 1,909 (31.3) 1,598 (29.0) 667 (27.7) 67 (25.7)
Receiving statins, n (%) 4,866 (68.7) 3,716 (61.0) 3,218 (58.5) 1,373 (57.0) 161 (61.7)
HbA1c at baseline, % 6.7 ± 1.2 7.8 ± 1.9 8.4 ± 2.1 8.9 ± 2.3 9.6 ± 2.5
HbA1c at baseline, mmol/mol 49 ± 13.0 62 ± 20.3 68 ± 23.1 77.4 ± 24.6 81 ± 26.8
HDL cholesterol, mmol/L 1.3 ± 0.4 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
Non-HDL cholesterol, mmol/L 3.5 ± 1.2 3.8 ± 1.2 3.9 ± 1.3 4.0 ± 1.3 4.0 ± 1.1
ALT, IU/L* 24 [18, 34] 28 [20, 39] 30 [21, 45] 32 [22, 48] 32 [22, 48]
eGFR, mL/min/1.73m2 72.2 ± 18.7 73.7 ± 18.8 77.2 ± 19.1 80.7 ± 19.7 84.1 ± 20.8
* Presented as median [the interquartile range]
Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; 
SIMD: Scottish Index of Multiple Deprivation
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Figures and figure legends
Figure 1.  The flow diagram of the patient selection
Abbreviations: ASCV: atherosclerotic cardiovascular; CKD: chronic kidney diseases; 
CV: cardiovascular; DFU: diabetic foot ulcer; DPN: diabetic peripheral neuropathy; 
DR: diabetic retinopathy; MACE: major adverse cardiovascular events.
Figure 2.  The association between HbA1c variability score and adverse 
outcomes in patients with newly diagnosed type 2 diabetes
Abbreviations: CI: confidence interval; HR: hazard ratio.
Figure 3.  The association between HbA1c variability score and adverse 
outcomes in patients with newly diagnosed type 2 diabetes after adjusting for the 
time-weighted average HbA1c
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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 Figure 1.  The flow diagram of the patient selection 
Abbreviations: ASCV: atherosclerotic cardiovascular; CKD: chronic kidney diseases; CV: cardiovascular; 
DFU: diabetic foot ulcer; DPN: diabetic peripheral neuropathy; DR: diabetic retinopathy; MACE: major 
adverse cardiovascular events. 
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 Figure 2.  The association between HbA1c variability score and adverse outcomes in patients with newly 
diagnosed type 2 diabetes 
Abbreviations: CI: confidence interval; HR: hazard ratio. 
423x635mm (72 x 72 DPI) 
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 Figure 3.  The association between HbA1c variability score and adverse outcomes in patients with newly 
diagnosed type 2 diabetes after adjusting for the time-weighted average HbA1c 
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability score. 
423x635mm (72 x 72 DPI) 
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Supplementary Techniques
Study exclusion criteria
They were excluded if they had: 1) unavailable data of sex, date of birth, Scottish 
Index of Multiple Deprivation (SIMD) or smoking records throughout the study 
period; 2) unavailable data of body mass index (BMI), serum creatinine or high-
density lipoprotein (HDL) cholesterol within a year since diagnosis of diabetes; 3) 
free of the record of Scottish diabetes routine check when analyzing the outcomes of 
diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), diabetic foot ulcer 
(DFU); 5) with the estimated glomerular filtrate rate (eGFR) lower than 60 mL/min 
per 1.73m2 at baseline when analyzing the outcome of new onset of chronic kidney 
diseases (CKD).
Defining the baseline characteristics
The patients were recognized to be ever smoking if there were any records of current 
or previous smoking in their the record in the electronic medical record (EMR) 
database. All baseline characteristics were using the data within a year since diagnosis 
of diabetes. BMI was extracted from the EMR database. The laboratory tests were 
extracted for the laboratory information systems. The eGFR was calculated using the 
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. 
Hypertension at baseline was identified if there were at least two episodes of elevated 
blood pressures in different days (systolic blood pressure >140mmHg or diatolic 
blood pressure >90mmHg), or receiving at least two prescriptions of the anti-
hypertensive drug (angiotensin-converting-enzyme inhibitors, angiotensin receptor 
blockers, renin inhibitors, beta-blockers or non-dihydroxypyridine calcium channel 
blockers). The baseline oral anti-diabetic agents (metformin, sulphonylureas, gliptins, 
acarbose, thiazolidinediones, dipeptidyl peptidase-4 inhibitors and sodium-glucose 
cotransporter-2 inhibitors), insulin, antiplatelet therapy and statins at baseline were 
identified if there were at least two prescriptions of the drug class within the first year 
of diagnosis. If the patients used insulin combined with oral agents, we considered 
insulin as a priority.
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Defining the outcomes
All-cause mortality was identified as any death record in the General Registry Office 
or the Community Health Index (CHI) registry. Cardiovascular death was identified 
as the death due to ischemic stroke (defined as ICD-9: 433, 434, 435 or 436; ICD-10: 
I63, I64, I65 or I66) or coronary artery disease (defined as ICD-9: 410, 411, 412, 413 
or 414; ICD-10: I20, I21, I22, I23, I24 or I25). The cardiovascular outcomes were 
identified if the patients were hospitalized or died due to the coronary artery disease, 
ischemic stroke or heart failure (defined as ICD-9: 428 or ICD10: I50), respectively. 
Major adverse cardiovascular events (MACE) was defined as a composite outcome of 
cardiovascular death, ischemic stroke and coronary artery diseases. DR was identified 
as the first episode of observable background or more advanced retinopathy according 
to the annual retinal photograph taken as part of the routine care or receiving a laser 
treatment based on the records in the Scottish Care Information-Diabetes 
Collaboration (SCI-DC). DPN and DFU were identified as the first episode of 
impaired monofilament test and the first record of active foot ulcer according to the 
record of the SCI-DC system as part of the routine care in Scotland, respectively. 
CKD was identified for the first episode of persistently reduced eGFR (all eGFR 
values in and between two nonadjacent months were below 60 mL/min per 1.73m2). 
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Table S1.  Baseline characteristics of patients for those included for each analysis of outcomes.
MACE 
(n = 
17,366)
All-cause 
mortality (n 
= 19.883)
Cardiovascu
lar death (n 
= 19,746)
Coronary 
artery disease 
(n = 16,413)
Ischemic 
stroke (n 
= 18,609)
Heart 
failure (n 
= 19,059)
Diabetic 
retinopathy 
(n = 15,067)
Diabetic 
peripheral 
neuropathy (n = 
13,111)
Diabetic 
foot ulcer 
(n = 15,913)
Chronic 
kidney 
disease (n = 
13,812)
Age of diabetes diagnosis, yrs 62.7 ± 
11.0
63.2 ± 11.0 63.1 ± 11.0 62.5 ± 11.0 62.9 ± 10.9 62.9 ± 
10.9
62.8 ± 10.7 62.3 ± 10.6 63.0 ± 10.8 59.5 ± 9.8
Sex (male), n (%) 9,202 
(53.0)
10,854 
(54.6)
10,777 (54.6) 8,594 (52.4) 10,080 
(54.2)
10,329 
(54.2)
8,206 (54.5) 7,061 (53.9) 8,577 (53.9) 8,418 (60.9)
SIMD quintile, n (%)
  Q1 3,246 
(18.7)
3,818 (19.2) 3,784 (19.2) 3,073 (18.7) 3,534 
(19.0)
3,636 
(19.1)
2,863 (19.0) 2,459 (18.8) 3,028 (19.0) 2,724 (19.7)
  Q2 3,265 
(18.8)
3,755 (18.9) 3,738 (18.9) 3,015 (18.4) 3,526 
(18.9)
3,597 
(18.9)
2,812 (18.7) 2,424 (18.5) 2,960 (18.6) 2,590 (18.8)
  Q3 3,282 
(18.9)
3,789 (19.1) 3,756 (19.0) 3,130 (19.1) 3,518 
(18.9)
3,620 
(19.0)
2,863 (19.0) 2,440 (18.6) 3,005 (18.9) 2,597 (18.8)
  Q4 4,710 
(27.1)
5,315 (26.7) 5,275 (26.7) 4,467 (27.2) 5,003 
(26.9)
5,114 
(26.8)
4,061 (27.0) 3,627 (27.7) 4,343 (27.3) 3,667 (26.5)
  Q5 2,863 
(16.5)
3,206 (16.1) 3,193 (16.2) 2,728 (16.6) 3,028 
(16.3)
3,092 
(16.2)
2,468 (16.4) 2,161 (16.5) 2,577 (16.2) 2,234 (16.2)
Year of diabetes diagnosis* 2009 
[2003, 
2011]
2009 [2003, 
2011]
2009 [2003, 
2011]
2009 [2003, 
2011]
2009 
[2003, 
2011]
2009 
[2003, 
2011]
2008 [2003, 
2010]
2006 [2002, 
2010]
2006 [2002, 
2010]
2009 [2004, 
2011]
BMI, kg/m2 32.2 ± 
6.4
32.1 ± 6.4 32.1 ± 6.4 32.2 ± 6.5 32.2 ± 6.4 32.1 ± 6.4 32.2 ± 6.3 32.0 ± 6.3 32.0 ± 6.3 32.6 ± 6.5
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Ever smoking, n (%) 12,065 
(69.5)
14,122 
(71.0)
14,019 (71.0) 11,310 (68.9) 13,125 
(70.5)
13,452 
(70.6)
10,774 
(71.5)
9,402 (71.7) 11,421 
(71.8)
9,790 (70.9)
Ever regular alcohol, n (%) 9,420 
(58.5)
10,823 
(58.7)
10,771 (58.8) 8,840 (58.3) 10,177 
(58.9)
10,410 
(58.9)
8,378 (59.0) 7,389 (59.6) 8,733 (58.3) 8,043 (63.0)
Systolic blood pressure, 
mmHg
141.1 ± 
19.3
140.6 ± 19.5 140.6 ± 19.4 141.4 ± 19.3 140.7 ± 
19.3
140.8 ± 
19.3
140.8 ± 19.2 141.4 ± 19.5 141.2 ± 19.6 139.9 ± 18.9
Diastolic blood pressure, 
mmHg
81.4 ± 
10.9
80.9 ± 11.1 80.9 ± 11.0 81.7 ± 10.9 81.1 ± 11.0 81.1 ± 
11.0
81.1 ± 10.9 81.5 ± 11.0 81.2 ± 11.0 82.0 ± 10.9
Carlson Comorbidity Index 
≥1, n (%)
2,599 
(15.0)
3,369 (16.9) 3,328 (16.9) 2,326 (14.2) 2,952 
(15.9)
3,064 
(16.1)
2,364 (15.7) 1,829 (14.0) 2,424 (15.2) 1,867 (13.5)
Hypertension, n (%) 12,166 
(70.1)
14,323 
(72.0)
14,214 (72.0) 11,311 (68.9) 13,282 
(71.4)
13,600 
(71.4)
10,916 
(72.4)
9,425 (71.9) 11,522 
(72.4)
9,282 (67.2)
Treatment of diabetes within 
the first year from the 
diagnosis of diabetes, n (%)
    
  Lifestyle intervention only 9,259 
(53.3)
10,685 
(53.7)
10,618 (53.8) 8,662 (52.8) 9,951 
(53.5)
10,255 
(53.8)
8,175 (54.3) 7,116 (54.3) 8,601 (54.1) 7,034 (50.9)
  Anti-diabetic agents without 
insulin
7,789 
(44.9)
8,791 (44.2) 8,727 (44.2) 7,443 (45.3) 8,279 
(44.5)
8,430 
(44.2)
6,585 (43.7) 5,724 (43.7) 6,990 (43.9) 6,522 (47.2)
  Treated with insulin 318 
(1.8)
407 (2.0) 401 (2.0) 308 (1.9) 379 (2.0) 374 (2.0) 307 (2.0) 271 (2.1) 322 (2.0) 256 (1.9)
Receiving anti-platelet 
therapy, n (%)
4,510 
(26.0)
6,232 (31.3) 6,170 (31.2) 3,832 (23.3) 5,459 
(29.3)
5,769 
(30.3)
4,790 (31.8) 4,049 (30.9) 5,052 (31.7) 3,555 (25.7)
Receiving statins, n (%) 10,385 
(59.8)
12,333 
(62.0)
12,252 (62.0) 9,592 (58.4) 11,391 
(61.2)
11,743 
(61.6)
9,238 (61.3) 7,680 (58.6) 9,513 (59.8) 8,472 (61.3)
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HbA1c, % 7.7 ± 
2.0
7.7 ± 2.0 7.7 ± 2.0 7.8 ± 2.0 7.7 ± 2.0 7.7 ± 2.0 7.7 ± 2.0 7.8 ± 2.0 7.8 ± 2.0 7.8 ± 2.0
HbA1c, mmol/mol 61 ± 
21.8
61 ± 21.6 61 ± 21.5 61 ± 22.0 61 ± 21.6 61 ± 21.5 61 ± 21.5 61 ± 22.1 61 ± 21.9 62 ± 22.0
HDL cholesterol, mmol/L 1.2 ± 
0.3
1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
Non-HDL cholesterol, 
mmol/L
3.9 ± 
1.2
3.8 ± 1.3 3.8 ± 1.3 3.9 ± 1.2 3.8 ± 1.2 3.8 ± 1.3 3.8 ± 1.2 3.9 ± 1.3 3.9 ± 1.3 3.9 ± 1.3
ALT, IU/L* 28 [20, 
41]
28 [20, 40] 28 [20, 40] 28 [20, 41] 28 [20, 41] 28 [20, 
40]
28 [20, 41] 28 [20, 41] 28 [20, 41] 30 [22, 44]
eGFR, mL/min/1.73m2 75.5 ± 
18.7
74.7 ± 19.0 74.8 ± 18.9 75.8 ± 18.8 75.1 ± 18.8 75.1 ± 
18.7
73.3 ± 18.1 73.4 ± 17.8 73.1 ± 18.1 83.0 ± 14.5
* Presented as median [the interquartile range]
Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; eGFR: estimated glomerular filtration rate; HDL: high-density 
lipoprotein; SIMD: Scottish Index of Multiple Deprivation
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Figure S1.  The definition of HbA1c Variability Score (HVS)
Δ1 = 1.2%
Δ2 = 0.4%
Δ3 = 2.3%
Δ4 = 0.3%Obs1
Obs2
Obs3
Obs4
Obs5
8.9%
8.5%
8.2%
7.0%
6.6%
HbA1c Variability Score (HVS) = Number of HbA1c fluctuation events 
(Δ>0.5%) / (Total number of HbA1c measurements – 1) × 100
In this case, there are 2 fluctuation events (Δ1 & Δ3) in 5 HbA1c 
measurements (4 Δs). ∴ HVS = 2 / (5 - 1) × 100 = 50
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Figure S2.  The subgroup analysis based on the age 
A.
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B.
A. the subgroup of patients younger than 65; B. the subgroup of patients aged 65 or 
older
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S3.  The subgroup analysis based on sex 
A.
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B.
A. the subgroup of female patients; B. the subgroup of male patients
Abbreviations: CI: confidence interval; HR: hazard ratio.
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Figure S4.  The subgroup analysis based on the baseline body mass
A.
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B.
A. the subgroup of non-obese patients at baseline; B. the subgroup of obese patients at 
baseline
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S5.  The subgroup analysis based on the time-weighted average HbA1c
A.
B.
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A. the subgroup of the time-weighted average HbA1c ≤7% (53 mmol/mol); B. the 
subgroup of the time-weighted average HbA1c >7% (53 mmol/mol)
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S6.  The subgroup analysis based on the treatment of diabetes at baseline
A.
B.
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A. the subgroup of patients receiving lifestyle intervention only at baseline; B. the 
subgroup of patients receiving anti-diabetic medication or insulin at baseline
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S7.  The sensitivity analysis using the binned HbA1c variability score (b-
HVS)
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S8.  The sensitivity analysis using the HbA1c variability score (HVS) based 
on the HbA1c measurement in the first three years since diagnosis 
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S9.  The sensitivity analysis using the standard deviation (SD) of the HbA1c 
levels in accordance with the HVS category 
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Figure S10.  The sensitivity analysis using the coefficients of variance (CV) of the 
HbA1c levels in accordance with the HVS category 
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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Abstract
Objective: To investigate the association between visit-to-visit HbA1c variability and 
cardiovascular events and microvascular complications in patients with newly 
diagnosed type 2 diabetes.
Research Design and Methods: This retrospective cohort study analyzed patients 
from Tayside and Fife in the Scottish Care Information-Diabetes Collaboration (SCI-
DC), who were observable from the diagnosis of diabetes and had at least five HbA1c 
measurements before the outcomes being evaluated. We used the previously reported 
HbA1c variability score (HVS) calculated as the percentage of the number of changes 
in HbA1c over 0.5% (5.5 mmol/mol) among all HbA1c measurement within an 
individual. The association between HVS and ten outcomes was assessed using Cox 
proportional-hazards models.
Results: We included 13,111 to 19,883 patients in the analyses of each outcome. The 
patients with HVS over 60% were associated with elevated risks of all outcomes 
compared with the lowest quintile (for example, hazard ratios and 95% confidence 
intervals [HVS >80 to ≤100 vs. HVS ≥0 to ≤20]: 2.38 [1.61~3.53] for major adverse 
cardiovascular events [MACE]; 2.4 [1.72~3.33] for all-cause mortality; 2.4 [1.13~5.11] 
for atherosclerotic cardiovascular [ASCV] death; 2.63 [1.81~3.84] for coronary artery 
disease; 2.04 [1.12~3.73] for ischemic stroke; 3.23 [1.76~5.93] for heart failure; 7.4 
[3.84~14.27] for diabetic retinopathy; 3.07 [2.23~4.22] for diabetic peripheral 
neuropathy; 5.24 [2.61~10.49] for diabetic foot ulcer; 3.49 [2.47~4.95] for the new-
onset chronic kidney disease). Four sensitivity analyses, including adjustment for time-
weighted average HbA1c confirmed the robustness of the results. 
Conclusions: Our study shows that higher HbA1c variability is associated with 
increased risks of all-cause mortality, cardiovascular events and microvascular 
complication of diabetes independently of high HbA1c. 
Keywords: HbA1c variability, cardiovascular event, all-cause mortality, heart failure, 
diabetic retinopathy, diabetic peripheral neuropathy, diabetic foot ulcer, chronic kidney 
disease
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Introduction
Although there is considerable evidence that intensive blood glucose normalization 
reduces the risk of both cardiovascular events and microvascular complications of 
diabetes (1-3), the effects were heterogeneous between trials. For example, the 
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was terminated 
prematurely due to significantly elevated mortality and cardiovascular events (4), 
suggesting that the near-normalization of blood glucose should not be the only target 
of diabetes treatment. Glycemic variability is one factor that may explain these 
differences in cardiovascular outcomes.
Glycemic variability can be measured as either the glucose fluctuation within a day or 
the long-term visit-to-visit variability. The latter has been recently investigated in 
several studies, although the metrics and definition of the variability measure were 
inconsistent (5). Most studies evaluating HbA1c variability using the standard deviation 
(SD) or the coefficient of variation (CV) of HbA1c, suggested that these measures were 
associated with all-cause mortality and the development of the adverse outcomes of 
diabetes, after adjusting for the average HbA1c (6-11). However, neither SD or CV of 
HbA1c can be easily interpreted in clinical practice. Recently, Forbes and colleagues 
(12) developed a new scale, namely the HbA1c variability score (HVS) in the current 
study, to define the HbA1c variability. The HVS indicates how frequently the HbA1c 
rises or decreases by more than 0.5% (5.5mmol/mol), which is in line with the SD and 
CV of HbA1c but clinically more translatable (as it can be interpreted as the percentage 
of total HbA1c measures that vary by more than 0.5% or 5.5mmol/mol) (6,12). 
However, the HVS has not been widely used among the studies of HbA1c variability, 
with previous studies using this scale only focusing on the elderly and non-diabetic 
population and evaluating mainly mortality as an outcome (6,12). It is unclear whether 
HVS is associated with microvascular complications of diabetes and whether the 
increased cardiovascular risk described could be extended to real-world patients with 
type 2 diabetes. In this study we aimed to investigate the association between visit-to-
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visit HbA1c variability and both cardiovascular diseases and microvascular 
complications in a large population database of patients with newly diagnosed type 2 
diabetes.
Research Design and Methods
Data source and study population
The population was selected from patients from Tayside and Fife in the Scottish Care 
Information-Diabetes Collaboration (SCI-DC), the electronic health record system used 
in Scotland for patients with diabetes. The patients were included if they: 1) were 
diagnosed with type 2 diabetes; 2) had their first HbA1c measurement within one year 
from diagnosis of diabetes; 3) were over 40 years old when first diagnosed with diabetes; 
4) did not experience any study outcome before or within three years since diagnosis of 
diabetes; 5) had at least five records of HbA1c measurement between diagnosis of 
diabetes and the first episode of the study outcome. Patients were excluded where data 
were incomplete (details see the Supplementary Techniques). Data provision and 
linkage were carried by the University of Dundee Health Informatics Centre (HIC, 
https://www.dundee.ac.uk/hic), with analyses of anonymized data performed in an 
ISO27001 and Scottish Government accredited secure safe haven. HIC Standard 
Operating Procedures have been reviewed and approved by the NHS East of Scotland 
Research Ethics Service and consent for this study was obtained from the NHS Fife 
Caldicott Guardian. 
Baseline parameters and follow-up
The body mass index (BMI), estimated glomerular filtration rate (eGFR), smoking 
status at baseline were captured from the medical record within one year from the 
diagnosis of diabetes (details see the Supplementary Techniques). The follow-up was 
defined by the first event of outcome or the last measurement of HbA1c before 24 April 
2017 in the event-free case. Charlson Co-morbidity Index (CCI) was calculated using 
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the ICD (International Classification of Diseases)-9 and ICD-10 code within the year 
after the diagnosis of diabetes (13), while we specifically removed the items of diabetes 
and cardiovascular events, which were overlapping with our population or outcomes. 
Assessment of visit-to-visit HbA1c variability
To avoid the interaction between the HbA1c variability parameter with the frequency 
of HbA1c measurement and to better fit clinical practice, the HbA1c variability was 
evaluated using HVS, which was adopted from a recent publication (12). Briefly, HVS 
is the number of measures within an individual where the HbA1c has changed by > 0.5% 
(5.5mmol/mol) from the value prior, as a percentage of the total number of HbA1c 
measures between the diagnosis of diabetes and the outcome of interest for that 
individual (Fig. S1). To avoid the impact of multiple HbA1c measures in a short space 
of time, we allocated one HbA1c measure for every three-month period, using the 
median of all the HbA1c measures within that time. The resulting variability measure 
is termed the binned HVS (b-HVS). We also calculated the time-weighted average 
HbA1c, which was calculated using the area under the curve (AUC) of HbA1c from the 
diagnosis of diabetes to the first event divided by the duration. 
Outcomes
We examined ten outcomes of interest including: major adverse cardiovascular events 
(MACE); all-cause mortality; atherosclerotic cardiovascular death (ASCV death); 
hospitalization or death from coronary artery disease, ischemic stroke or heart failure; 
observable background diabetic retinopathy (DR), diabetic peripheral neuropathy 
(DPN); diabetic foot ulcer (DFU); and the new onset of chronic kidney diseases (CKD). 
If the event of interest occurred within the first three years from the diagnosis of 
diabetes, the patient was excluded from the analysis of that outcome, to avoid the 
outcome occurring close to diagnosis before the HVS could be defined, when the 
outcome would be unlikely to be related to the HVS. For full definitions of the 
endpoints (see the Supplementary Techniques).
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Statistical Analyses
The categorical variables were described using frequency and percentage. The 
continuous variables were described using means and SDs if normally distributed or 
median interquartile range (IQR) if not. Cox proportional-hazards model was used to 
assess the association between the HbA1c variability and each of the outcomes. The 
association of the adverse outcome with the HVS categories (≥0 to ≤20, >20 to ≤40, >40 
to ≤60, >60 to ≤80, >80, with the ≥0 to ≤20 as reference) were adjusted for sex, index 
age, calendar year, Scottish Index of Multiple Deprivation (SIMD) quintiles, ever 
smoking, hypertension at baseline, BMI at baseline, high-density lipoprotein (HDL) 
cholesterol at baseline, eGFR at baseline, antiplatelet therapy at baseline and CCI (≥1 
vs 0). We used Survival::cox.zph Pack in R to test the proportional hazards assumption 
for Cox regression models (14) for all our models. We considered the proportional 
hazards assumptions to be violated if the global P-value lower than 0.01. Because of 
the violation of proportional hazards assumptions the stage of CKD (stage 1 or 2) at 
baseline rather than the eGFR at baseline was stratified in the analysis of the new onset 
of the CKD. Five subgroup analyses were introduced based on the age (<65 years vs 
≥65 years), sex, BMI at baseline (>30kg/m2 vs ≤30kg/m2), time-weighted mean HbA1c 
(>7% vs ≤7% or >53mmol/mol vs ≤53mmol/mol), and treatment at baseline 
(medication/insulin-treated vs. lifestyle intervention only). Five sensitivity analyses 
were performed for each outcome by: 1) adjusting for time-weighted average HbA1c; 
2) using the b-HVS instead of HVS; 3) using the HVS based on the HbA1c 
measurement solely focusing on the first three years after diagnosis of diabetes, prior 
to the occurrence of any event; 4) using the individual-level SDs of the HbA1c instead 
of the HVS; 5) using individual-level CVs of HbA1c instead of the HVS. Analyses 
were undertaken in the SAS® 9.4 (SAS Institute Inc., Cary, NC, USA). and the RStudio 
for Windows (R version 3.2.5). 
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Results
Baseline characteristics
As shown in Fig. 1, among the 79,569 patients with type 2 diabetes identified in the 
population, we included 21,352 patients for further analysis., The average age was 63.3 
± 11.1 years when recruited and 54.6% of them were male. The median follow-up 
duration was 6.8 (IQR: 4.6~11.2) years. The mean HbA1c at baseline was 7.7% ± 2.0% 
(60.7 ± 21.4 mmol/mol), and the median number of HbA1c measurements throughout 
the study period was 12 (IQR: 8~19) times during the follow-up duration. Tab. S1 
shows the baseline patient characteristics for those included for each analysis of 
outcomes and Tab. 1 shows how the baseline characteristics differ across the HVS 
categories. 62% of the patients have an HVS below or equal to 40%; 12.5% have an 
HVS greater than 60%. As expected, an increasing HVS is associated with younger age 
of diagnosis, higher BMI, and more intensive diabetes treatment including greater 
insulin use.
HbA1c variability and outcomes
As shown in Fig. 2, between 13,111 to 19,883 patients were involved in the analyses 
of each outcome. Comparing with the reference (lowest HVS category, ≥0 to ≤20), 
patients with HVS over 60 were associated with increased risks of all outcomes in a 
fully adjusted Cox model. For example, those with HVS >80 to ≤100 had an increased 
risk of (HR [95%CI]): MACE: 2.38 [1.61~3.53]; all-cause mortality: 2.4 [1.72~3.33]; 
ASCV death: 2.4 [1.13~5.11]; coronary artery disease: 2.63 [1.81~3.84]; ischemic 
stroke: 2.04 [1.12~3.73]; heart failure: 3.23 [1.76~5.93]; DR: 7.4 [3.84~14.27]; DPN: 
3.07 [2.23~4.22]; DFU: 5.24 [2.61~10.49]; CKD: 3.49 [2.47~4.95]). 
Subgroup analyses and sensitivity analyses
Given the association between HVS and HbA1c we first undertook a sensitivity analysis, 
including time-weighted average HbA1c from diagnosis to event in the models (Fig. 
3). The results were similar for most outcomes other than retinopathy where the 
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association of HVS was diminished when adjusting for the time-weighted average 
HbA1c. 
When comparing the subgroups with time-weighted average HBA1c more than or less 
than 7% (53mmol/mol) there was a stronger association between the HVS and coronary 
artery disease, ischemic stroke and progression to CKD in patients with time-weighted 
average HbA1c<7% or 53mmol/mol (Fig. S5). Other subgroup analyses were 
undertaken based on age (Fig. S2), sex (Fig. S3), obesity at baseline (Fig. S4) and 
treatment at baseline (Fig. S6) did not show significant differences in the trend of the 
association (except the cases with very small sample size). Using b-HVS instead of 
HVS also showed consistent results in all outcomes (Fig. S7). However, the sensitivity 
analysis using the first-three year HVS suggested a weaker association compared with 
the main analysis (Fig. S8). The sensitivity analysis using the individual-level SD (Fig. 
S9) and CV (Fig. S10) of HbA1c showed a similar pattern of risk for most outcomes 
but not ischemic stroke for SD and CV and diabetic retinopathy for CV where weaker 
associations were observed.
Discussion
To our knowledge, this is the first population-based study to investigate the association 
between the visit-to-visit HbA1c variability and comprehensive endpoints including 
cardiovascular events and the microvascular complications of diabetes in patients with 
newly diagnosed type 2 diabetes independent of the time-weighted average HbA1c. 
Our study showed clear elevated risks of adverse events in the ~12.5% of patients with 
a HVS higher than 60 (meaning those with 60% of their HbA1c measurements 
increased or decreased by > 0.5% (5.5mmol/mol) compared with the last measurement) 
after diagnosis of diabetes adjusted for their time-weighted average HbA1c. The results 
were consistent with previous studies based on trial (15,16) and observational datasets 
(6-12,17). Our results indicate that frequent fluctuations of HbA1c of patients with 
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diabetes may be an independent risk factor of poor prognosis and more stable HbA1c 
control may benefit the patients in clinical practice, although it should be emphasized 
that our results are observational and causal inference cannot be made. Of note, a recent 
analysis based on the VADT trial (16) suggested that higher HbA1c variability was 
associated with the increased risk of cardiovascular events in the group of intensive 
glycemic control but not the standard control. It suggested that the increased HbA1c 
variability may neutralize the cardiovascular benefits of the sustained 1.5% (16.4 
mmol/mol) HbA1c reduction during the study period (18). We undertook a subgroup 
analysis looking at HVS in those with good and poor average HbA1c. It was interesting 
to note that the HVS association with atherosclerotic cardiovascular events was greater 
in those with good HbA1c, in keeping with the VADT finding. However, we need to 
interpret these results with caution as we can not account for treatment intensity during 
the study period.
We have previously reported that patients with high variability in HbA1c have high 
cardiovascular risk at baseline (19), and thus the association of HbA1c variability with 
risk may not be a feature of the HbA1c variability per se, but a marker of this baseline 
difference in patient characteristics. In this current study we have adjusted 
comprehensively for baseline differences in cardiovascular risk although we 
acknowledge there could be residual confounding. It is interesting to note that in the 
sensitivity analysis where we restrict our analysis to defining HbA1c variability only 
on the first three years of HbA1c measures, the association with micro- and 
macrovascular outcomes are diminished. This suggests that the HbA1c variability may 
continuously contribute to the clinical adverse endpoints beyond the first three years, 
and therefore that the risk can be less attributable to baseline differences in patient 
characteristics and more attributable to the HbA1c variability per se. As a recent study 
suggested that HbA1c variability is associated with the quality of patient care (20), it 
also suggests that it is never too late to reduce the HbA1c variability in clinical practice. 
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Although infeasible in the current analysis, it would also be interesting to evaluate 
HbA1c variability on different anti-diabetic treatments to see if reduced variability can 
explain some of the improved outcomes with some of these agents. 
Although we cannot attribute poor prognosis to the HbA1c variability per se, some 
underlying mechanisms may explain the association observed in our study. Although 
oxidative stress is suggested to be the explanation between short-term glycemic 
variability and adverse outcomes (5), it is not clear whether this is increased in patients 
with high visit-to-visit HbA1c variability. An alternative may relate to accumulated 
epigenetic modification induced by both high and low glycemia (21). Another 
explanation may simply relate to increased hypoglycemia in these individuals, since 
some studies suggest high HbA1c variability is linked to increased risk of severe 
hypoglycemic episodes (22) and patients admitted to hospital due to hypoglycemia have 
higher HbA1c variability (23). It will be valuable if a further study could address the 
frequency of overall and severe hypoglycemia among patients with different HbA1c 
variability.
The strengths of our study are clear. Firstly, all the included patients were tracked with 
their HbA1c measurement from the diagnosis of diabetes, so there is no period of the 
patients' diabetes journey that is not captured. Secondly, we comprehensively studied 
ten clinically important outcomes, including all-cause mortality, cardiovascular events 
and major microvascular complications of diabetes and showed consistent results 
across these micro- and macrovascular endpoints. Thirdly, our results were confirmed 
by a series of subgroup analyses and sensitivity analyses including adjusting for the 
time-weighted average HbA1c from the diagnosis of diabetes. Fourthly, our study was 
based on the real-world data of diabetes care in Scotland making these results directly 
translatable to clinical practice. Finally, we have used the HVS rather than SD or CV 
which we feel is much more clinically tractable. Although SD and CV reflect the 
dispersion trend of the HbA1c measures in an individual, they are no more than 
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clinically meaningless statistical parameters. When considering the HVS, the clinicians 
can review the HbA1c profile for an individual – those where more than 60% of 
measures vary by more than 0.5% are at high risk.
The study does have limitations. Firstly, as a retrospective cohort study, uncorrected 
confounding could be possible and individuals with higher HbA1c variability may also 
at higher cardiovascular risks of other causes (18), and we cannot conclude an 
association of variability per se with the outcomes. Nevertheless, we used Cox 
proportional-hazards models to minimize the possible known confounding factors 
including CCI, smoking status and social deprivation and used a series of subgroup 
analyses and sensitivity analyses to confirm our findings to be robust. Secondly, we did 
not adjust for or evaluate the contribution of hypoglycemia, which has been reported to 
be associated with HbA1c variability (15) in the association between the HbA1c 
variability and outcomes because of the limitation of the data. Thirdly, the median 
follow-up duration of the study was 6.8 years and this will limit the total incident 
outcomes. The need to only include patients with newly diagnosed diabetes and other 
inclusion criteria do limit the total follow up time in this study population. This 
relatively short median duration does reduce the number of long-term outcome events 
especially for retinopathy and diabetic foot ulcer. Studies with longer follow-up 
duration in larger populations would be of value.
Conclusion
In conclusion, our study shows that higher HbA1c variability from the diagnosis of 
diabetes is independently associated with increased risks of all-cause mortality, major 
cardiovascular and microvascular complications of diabetes. 
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Table and table legend
Table 1.  Baseline characteristics of the overall study population
HVS Scores ≥0 to ≤20 >20 to ≤40 >40 to ≤60 >60 to ≤80 >80
n 7,084 6,096 5,502 2,409 261
Age of diabetes diagnosis, yrs 67.1 ± 10.3 63.5 ± 10.5 60.5 ± 10.9 58.9 ± 11.2 57.5 ± 11.2
Sex (male), n (%) 3,569 (50.4) 3,305 (54.2) 3,179 (57.8) 1,446 (60.0) 165 (63.2)
SIMD quintile, n (%)
  Q1 1,251 (17.7) 1,165 (19.1) 1,171 (21.3) 503 (20.9) 62 (23.8)
  Q2 1,263 (17.8) 1,134 (18.6) 1,121 (20.4) 471 (19.6) 51 (19.5)
  Q3 1,328 (18.7) 1,175 (19.3) 1,016 (18.5) 493 (20.5) 52 (19.9)
  Q4 1,936 (27.3) 1,629 (26.7) 1,409 (25.6) 634 (26.3) 60 (23.0)
  Q5 1,306 (18.4) 993 (16.3) 785 (14.3) 308 (12.8) 36 (13.8)
Year of diabetes diagnosis* 2010 [2005, 
2012]
2008 [2002, 
2011]
2008 [2002, 
2011]
2009 [2003, 
2011]
2010 [2006, 
2013]
BMI, kg/m2 31.3 ± 6.0 31.9 ± 6.2 32.8 ± 6.5 33.3 ± 7.1 33.2 ± 7.3
Ever smoking, n (%) 4,881 (68.9) 4,336 (71.1) 3,977 (72.3) 1,748 (72.6) 178 (68.2)
Ever regular alcohol, n (%) 4,008 (61.2) 3,345 (59.1) 2,875 (57.3) 1,185 (54.5) 131 (56.5)
Systolic blood pressure, mmHg 140.1 ± 19.0 141.2 ± 19.5 140.3 ± 19.8 139.6 ± 19.6 138.2 ± 19.4
Diastolic blood pressure, mmHg 78.9 ± 10.8 81.0 ± 10.9 82.2 ± 11.2 82.2 ± 11.4 82.2 ± 12.0
Carlson Comorbidity Index ≥1, n (%) 1,332 (18.8) 1,073 (17.6) 867 (15.8) 449 (18.6) 58 (22.2)
Hypertension, n (%) 5,505 (77.7) 4,376 (71.8) 3,786 (68.8) 1,574 (65.3) 155 (59.4)
Treatment of diabetes within the first year from the 
diagnosis of diabetes, n (%)
  Lifestyle intervention only 5,260 (74.3) 3,137 (51.5) 2,190 (39.8) 740 (30.7) 61 (23.4)
  Anti-diabetic agents without insulin 1,770 (25.0) 2,821 (46.3) 3,153 (57.3) 1,569 (65.1) 188 (72.0)
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  Treated with insulin 54 (0.8) 138 (2.3) 159 (2.9) 100 (4.2) 12 (4.6)
Receiving anti-platelet therapy, n (%) 2,465 (34.8) 1,909 (31.3) 1,598 (29.0) 667 (27.7) 67 (25.7)
Receiving statins, n (%) 4,866 (68.7) 3,716 (61.0) 3,218 (58.5) 1,373 (57.0) 161 (61.7)
HbA1c at baseline, % 6.7 ± 1.2 7.8 ± 1.9 8.4 ± 2.1 8.9 ± 2.3 9.6 ± 2.5
HbA1c at baseline, mmol/mol 49 ± 13.0 62 ± 20.3 68 ± 23.1 77.4 ± 24.6 81 ± 26.8
HDL cholesterol, mmol/L 1.3 ± 0.4 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
Non-HDL cholesterol, mmol/L 3.5 ± 1.2 3.8 ± 1.2 3.9 ± 1.3 4.0 ± 1.3 4.0 ± 1.1
ALT, IU/L* 24 [18, 34] 28 [20, 39] 30 [21, 45] 32 [22, 48] 32 [22, 48]
eGFR, mL/min/1.73m2 72.2 ± 18.7 73.7 ± 18.8 77.2 ± 19.1 80.7 ± 19.7 84.1 ± 20.8
* Presented as median [the interquartile range]
Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; 
SIMD: Scottish Index of Multiple Deprivation
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Figures and figure legends
Figure 1.  The flow diagram of the patient selection
Abbreviations: ASCV: atherosclerotic cardiovascular; CKD: chronic kidney diseases; 
CV: cardiovascular; DFU: diabetic foot ulcer; DPN: diabetic peripheral neuropathy; 
DR: diabetic retinopathy; MACE: major adverse cardiovascular events.
Figure 2.  The association between HbA1c variability score and adverse 
outcomes in patients with newly diagnosed type 2 diabetes
Abbreviations: CI: confidence interval; HR: hazard ratio.
Figure 3.  The association between HbA1c variability score and adverse 
outcomes in patients with newly diagnosed type 2 diabetes after adjusting for the 
time-weighted average HbA1c
Abbreviations: CI: confidence interval; HR: hazard ratio; HVS: HbA1c variability 
score.
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